Response to CMS Proposal on ESAs
In a recent letter to Steve Phurrough, MD, of the Centers for Medicare & Medicaid Services (CMS), Joseph S. Bailes, MD, chair of ASCO's Government Relations Council, asked that CMS withdraw its proposed decision memorandum regarding coverage of erythropoiesis-stimulating agents (ESAs) in nonrenal disease indications
ARLINGTON, VirginiaIn a recent letter to Steve Phurrough, MD, of the Centers for Medicare & Medicaid Services (CMS), Joseph S. Bailes, MD, chair of ASCO's Government Relations Council, asked that CMS withdraw its proposed decision memorandum regarding coverage of erythropoiesis-stimulating agents (ESAs) in nonrenal disease indications (see ONI, June 2007, page 43).
"In our view, the proposal is premature and should be withdrawn pending future decisions by the FDA," Dr. Bailes wrote. "We do not believe that the lawful decision of FDA concerning recommendations for usage should be preempted by CMS's coverage decision, which is not only inconsistent with the Medicare statute but also unsupported by the available medical evidence . . ."
Oncology Peer Review On-The-Go: Cancer Care Management During the COVID-19 Pandemic
October 28th 2020The newest episode of Oncology Peer Review On-The-Go speaks with 2 authors of an article from the October Issue of the journal ONCOLOGY focusing on effective cancer care management during the coronavirus pandemic.
